Italia markets open in 1 hour 18 minutes
Dow Jones
39.069,59 +4,29 (+0,01%) Nasdaq
16.920,79 +184,79 (+1,10%) Nikkei 225
38.813,86 +167,75 (+0,43%) EUR/USD
1,0852 +0,0002 (+0,02%) Bitcoin EUR
63.122,89 -508,09 (-0,80%) CMC Crypto 200
1.492,54 +24,44 (+1,66%)
Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 04:00PM EDT
Dopo ore:
| Chiusura precedente | 140,51 |
| Aperto | 140,51 |
| Denaro | 139,36 x 100 |
| Domanda | 139,52 x 100 |
| Min-Max giorno | 139,34 - 142,15 |
| Intervallo di 52 settimane | 89,04 - 148,37 |
| Volume | |
| Media Volume | 840.395 |
| Capitalizzazione | 14,029B |
| Beta (mensile su 5 anni) | 0,28 |
| Rapporto PE (ttm) | 37,88 |
| EPS (ttm) | 3,68 |
| Prossima data utili | 30 lug 2024 - 05 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 29 dic 1995 |
| Stima target 1A | 158,60 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.